1. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting. (June 2021) Authors: Geirnaert, Marc; Howarth, Jacy; Martin, Kristen; Ricard, Chad; Streilein, Scott; Wasney, Danica; Dao, Vi; Kotb, Rami; Rimmer, Emily; Minuk, Leonard Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 4(2021) Page Start: 907 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Autoimmune heparin‐induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Issue 6 (23rd March 2019) Authors: Arcinas, Liane A.; Manji, Rizwan A.; Hrymak, Carmen; Dao, Vi; Sheppard, Jo‐Ann I.; Warkentin, Theodore E. Journal: Transfusion Issue: Volume 59:Issue 6(2019) Page Start: 1924 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗